Jiangsu Hengrui Pharmaceuticals Co., Ltd. Investment Quality Review (600276.SH)

Data timestamp: 2026-07-13 22:10 UTC
Quality score: 64/100 Valuation position: price/base fair value 4.18 Final signal: AVOID

Core View

600276.SH does not clear the quality, cash-flow, or evidence gate for purchase in this review. The current price is 55.75CNY, versus conservative/base fair value of 10.79/13.33CNY. The investment conclusion is unchanged from the Chinese report: AVOID is a valuation-and-evidence decision, not a price target promise.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is assessed in healthcare, with the main tags china-a, healthcare, pharma, turnaround. The quality score is 64/100. The memo treats the company as below the good-company threshold but keeps the signal constrained by valuation, cash-flow repeatability, and primary-source evidence.

Business Quality

The business breakdown is used as support for quality and multiple selection, not as a separate valuation shortcut. Where five-year segment profit or margin has not been continuously verified, the report does not infer a segment-level valuation anchor.

16/20: five-year average FCF 43.4亿元，latest-year FCF/Revenue 26.2%、FCF/Net Income 1.07

9/10: latest-year cash and equivalents 409.6亿元、total debt 7423.3万CNY

7/10: revenue CAGR 5.1%、FCF CAGR 34.2%

Management and accounting are scored conservatively because dividends, buybacks, incentives, dilution, related-party matters, abnormal items, and audit observations still need item-by-item primary-source verification. That evidence cap is part of the signal discipline and should not be relaxed without official filings.

Financial Audit

The audit uses FY2021-FY2025, financial currency CNY, and quote currency alignment from the source report. No FX conversion is needed. The valuation references the same-currency 10-year sovereign rate of 1.74% from ChinaBond government yield curve dated 2026-07-13. ROIC is not used as a core positive when the unified baseline cannot reconstruct it reliably.

Latest fiscal year (FY2025) revenue was CNY 31.6bn, net income CNY 7.7bn, OCF CNY 11.2bn, capex CNY 3.0bn, and FCF CNY 8.3bn. FCF/Revenue was 26.2%, FCF/Net Income was 1.07, ROE was 14.3%, and ROIC was 12.9%.

The financial baseline can support the valuation work only if abnormal gains, receivables, inventories, goodwill, financial-asset composition, off-balance-sheet obligations, dividends, buybacks, and dilution remain consistent with the current thesis when checked against filings.

Valuation

The valuation uses normalized five-year FCF as the main anchor, then bridges to common-equity value with cash, current financial assets, non-current financial assets, and debt. It does not double-count dividends or buybacks that have not been independently verified.

Conservative fair value: 10.79CNY per share.
Base fair value: 13.33CNY per share.
Current price/base FV: 4.18.
The base case uses normalized FCF 56.1亿元，holding the current quality band, g 1%-3%，9x，matching a sub-threshold quality case, and produces 13.33CNY per share with price/FV 4.18.
The optimistic case reaches 18.06CNY with price/FV 3.09; it still requires segment growth and shareholder-return evidence to be confirmed from primary sources.

If revenue or FCF falls below the base anchor, fair value should be cut. If primary evidence supports stronger FCF durability and capital allocation, the base case can be revisited.

Buy And Tracking Discipline

The report stays at AVOID because quality, cash-flow durability, or evidence strength does not support a buy decision even where simple valuation may look inexpensive.

The buy condition remains price/base FV below 0.70, together with the next annual or interim report continuing to support the FCF anchor and the management/accounting score. A 2x base-case setup requires price/base FV below 0.50 or new primary evidence that lifts base fair value to more than twice the current price.

Tracking priorities are the five-year FCF anchor, segment revenue and profit, dividends/FCF, buyback price, incentive dilution, related-party transactions, regulatory changes, and any change in product/channel competitiveness.

Risks To Recheck

The main live risks are FCF quality, balance-sheet bridge accuracy, governance and accounting evidence, and shareholder-return evidence. FCF below the base anchor reduces fair value; financial-asset discounts, debt, and contingent obligations affect common-equity value; and unverified abnormal items, related-party matters, incentives, or audit issues keep the signal from being upgraded.

A positive reset needs FCF to stay above the base anchor for two complete periods, official evidence that dividends or buybacks are covered by repeatable FCF, and no deterioration in moat, regulation, channel economics, or pricing. A downgrade is triggered by FCF/Net Income staying below 0.60, weaker segment economics, harmful dilution, or official disclosures that undermine the accounting baseline.

Sources

The report relies on public quote and financial aggregation for price, market value, shares, and five-year baseline data; the relevant exchange or company disclosure venue for annual reports, interim reports, dividends, buybacks, governance, related-party transactions, incentives, and risk disclosures; same-currency sovereign yield data for the risk-free rate; and public FX data where financial and quote currencies differ.

Research note: This memo is for personal research only and is not personalized investment advice.